Acrivon Therapeutics
ACRV
55 hedge funds and large institutions have $161M invested in Acrivon Therapeutics in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 7 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 14
18% more capital invested
Capital invested by funds: $136M → $161M (+$24.7M)
0% more funds holding
Funds holding: 55 → 55 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
1.81% less ownership
Funds ownership: 75.99% → 74.18% (-1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.37M |
| 2 |
EAM
Exome Asset Management
New York
|
+$920K |
| 3 |
State Street
Boston,
Massachusetts
|
+$372K |
| 4 |
Millennium Management
New York
|
+$313K |
| 5 |
PCM
Prelude Capital Management
New York
|
+$297K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$3.83M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$851K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$218K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$205K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
51
Sterling Capital Management
Charlotte,
North Carolina
| $259 | +$292 | +37 | New |
|
|
CPA
52
Capital Performance Advisors
Walnut Creek,
California
| $224 | +$252 | +32 | New |
|
|
PBA
53
Paradigm Biocapital Advisors
New York
| – | -$3.83M | -659,724 | Closed |
|
54
Jane Street
New York
| – | -$178K | -30,714 | Closed |
|
55
Squarepoint
New York
| – | -$99.8K | -17,207 | Closed |
|
56
Walleye Capital
New York
| – | -$73.8K | -12,721 | Closed |
|
|
OQS
57
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
| – | -$72.8K | -12,552 | Closed |
|
|
XT
58
XTX Topco
George Town,
Cayman Islands
| – | -$60.9K | -10,493 | Closed |
|
59
Osaic Holdings
Scottsdale,
Arizona
| – | -$29.5K | -5,080 | Closed |
|
60
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$181 | +23 | +100% |
|
ACRV Hedge Fund Activity: Q3 2024 in Review
55 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q3 2024, worth a combined $161M — up 18% from $136M a quarter earlier.
Fund positioning in ACRV was balanced in Q3 2024: 7 funds opened new positions, 7 closed out, 18 added to existing stakes and 14 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $1.37M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $3.83M sold.
- 55 institutional investors held Acrivon Therapeutics (ACRV) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $161M of Acrivon Therapeutics stock for Q3 2024, up 18% quarter-over-quarter.
- 7 funds opened new Acrivon Therapeutics positions in Q3 2024 and 7 closed out, a net change of 0 holders.
- The largest Acrivon Therapeutics buyer in Q3 2024 was Goldman Sachs, an estimated $1.37M added.
- The largest Acrivon Therapeutics seller in Q3 2024 was Paradigm Biocapital Advisors, an estimated $3.83M sold.
Based on aggregated 13F filings for Q3 2024.